GM-CSF modified MB49 vaccine

GM-CSF modified MB49 vaccine is an **experimental cancer vaccine** created by immobilizing **granulocyte-macrophage colony-stimulating factor (GM-CSF)** on the surface of MB49 bladder cancer cells using protein-anchor technology (often via streptavidin-tagging and biotinylation)[1][2][3]. The vaccine aims to induce specific antitumor immune responses by promoting the maturation and recruitment of dendritic cells, increasing CD4(^+^) and CD8(^+^) T cells at tumor sites, and stimulating cytotoxic T lymphocyte activity against MB49 bladder cancer in preclinical mouse models[1][2][3]. The primary indication is for **metastatic bladder cancer** in preclinical models. This approach is part of a broader category of GM-CSF-based cellular cancer immunotherapies, which utilize GM-CSF to enhance antigen presentation and immune response to tumor cells[4]. The developer appears to be academic and research groups (see authors Chun-yan Wang et al.[3]), not commercial pharmaceutical companies. There is no evidence of commercial manufacturing or clinical development beyond animal studies.

Other names

GM-CSF modified MB49 vaccineGM-CSF surface-modified MB49 vaccineSA-GM-CSF MB49 vaccinemouse GM-CSF surface-modified MB49 cell vaccine